NIDA-1 P50 DA 018185: DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF R

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一项人体实验室临床药理学研究，旨在评估静脉注射甲基苯丙胺和利瓦斯明之间的潜在相互作用，以评估利瓦斯明治疗甲基苯丙胺依赖的安全性和可能的疗效。 主要： ？确定与安慰剂相比，使用活性药物治疗如何改变 甲基苯丙胺对心血管的影响 ？确定与安慰剂相比，使用活性药物治疗如何改变 甲基苯丙胺产生的主观和强化效应。 ？确定与安慰剂相比，使用活性药物治疗如何改变渴求 以及由甲基苯丙胺引发的寻毒行为。 次要：确定与安慰剂相比，使用活性药物治疗如何改变 神经认知功能。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a human laboratory clinical pharmacology study to assess potential interactions between intravenous methamphetamine and rivastigmine, in order to assess the safety and the likely efficacy of rivastigmine for the treatment of methamphetamine dependence. Primary: ¿ To determine how treatment with an active medication, compared to placebo, alters cardiovascular effects produced by Methamphetamine ¿ To determine how treatment with an active medication, compared to placebo, alters subjective and reinforcing effects produced by methamphetamine. ¿ To determine how treatment with an active medication, compared to placebo, alters craving and drug-seeking behavior produced by methamphetamine. Secondary: To determine how treatment with an active medication, compared to placebo, alters neurocognitive functioning.